^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    S81694

    i
    Other names: S81694, NMS-P153, S 81694, NMS P153, NMSP153
    Company:
    Nerviano Medical Sciences, Servier
    Drug class:
    TTK inhibitor
    Related drugs:
    over4years
    Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL) (ASH 2019)
    A small molecule Mps1i (S81694) was tested alone (0 to 1000nM) or in combination with imatinib, dasatinib, nilotinib and ponatinib in BCR-ABL1+ ALL cell lines. Mps1i S81694 yields significant preclinical activity in T-and B-cell ALL including BCR-ABL1+ models. Interestingly S81694 was efficacious in a TKI resistant cell line.
    Preclinical
    |
    ABL1 (ABL proto-oncogene 1)
    |
    dasatinib • imatinib • Iclusig (ponatinib) • Tasigna (nilotinib) • S81694